Premium
Reduced fetal exposure to aspirin using a novel controlled‐release preparation in normotensive and hypertensive pregnancies
Author(s) -
Regan Carmen L.,
McAdam Brendan F.,
McParland Peter,
Boylan Peter C.,
FitzGerald Garret A.,
Fitzgerald Desmond J.
Publication year - 1998
Publication title -
bjog: an international journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.157
H-Index - 164
eISSN - 1471-0528
pISSN - 1470-0328
DOI - 10.1111/j.1471-0528.1998.tb10203.x
Subject(s) - aspirin , thromboxane , prostacyclin , medicine , metabolite , preeclampsia , placebo , urinary system , thromboxane b2 , fetus , thromboxane a2 , urine , pharmacology , anesthesia , pregnancy , endocrinology , platelet , biology , pathology , alternative medicine , genetics
Objectives To examine the fetal effects of a novel controlled‐release, low dose aspirin preparation in normal and hypertensive pregnancies. Design Random double‐blind study. Participants assigned to receive conventional formulation aspirin (75 mg), controlled‐release low dose aspirin (75 mg), or matching placebo. Setting National Maternity Hospital, Dublin. Participants Eighteen women with an uncomplicated pregnancy and 18 women with preeclampsia. Main outcome measures Urine was analysed for metabolites of thromboxane and prostacyclin by gas chromatography, mass spectrometry. Serum thromboxane B 2 , was determined in maternal and cord blood. Results Both aspirin preparations reduced maternal serum thromboxane B 2 , by 95% and induced similar reductions in the urinary 11‐dehydro‐thromboxane B 2 , a major metabolite of thromboxane A 2 in vivo. In contrast, neither preparation altered urinary 2,3–dinor‐6‐keto PGF 1α , the major metabolite of prostacyclin. Despite their similar effects in the mothers, the two aspirin preparations differed in their effects on the fetus. While both suppressed cord fetal thromboxane B 2 , this was significantly ( P < 0.005 ) less for the controlled‐release preparation (210 ± 42 ng/ml for placebo vs 109 ± 22 ng/ml for controlled‐release aspirin and 44 ± 9 ng/ml for regular oral aspirin). Conclusions At equivalent maternal suppression of serum thromboxane B 2 , a controlled aspirin release preparation results in lower fetal exposure than regular oral aspirin.